Venus Remedies Ltd has launched commercially a new formulation developed by the in-house R & D wing, belongs to the Critical Care and ventilation therapy in its Parenteral Specialty Division for domestic markets.

According to a company release, the new product launched under the brand name of Mucomelt, is a specialty product for the treatment of diseases of the respiratory segment. Mucomelt is an essential drug for patients under Intensive Care and Immuno-compromised patients. It restores respiration during critical stages and substantially reduces the duration of hospitalization and the incidence of multi-organ dysfunction sybdrome, inhibits esophageal tumours and potentiates the effect of anti-angina drugs. It is a potent De-toxifier and prevents radio contrast induced nephropathy, which makes it an ideal drug for patients of ICU, ARDS, COPD, AIDS, Cancer, Angina Pectoris and MI. It is a highly safe drug with well- established safety profile for patients of all ages, from pre-term infants to geriatric patients, said the release.